DELFI Diagnostics, Inc., developer of accessible blood-based liquid biopsy tests that deliver a new way to enhance early cancer detection, is announcing the appointment of Robert Guigley as its new Chief Commercial Officer. Drawing on decades of biotechnology and diagnostics experience, Guigley will help shape DELFI’s strategic vision to expand market access and bring breakthrough liquid biopsy technology to healthcare providers and patients.
“Rob is an experienced executive leader in healthcare commercialization and is known for fostering a culture of innovation and collaboration that aligns with our approach to growth,” said Susan Tousi, CEO of DELFI Diagnostics. “With a background in executive-level sales, market access, revenue management, and product strategy and development, Rob will help us drive market opportunities and achieve profitable growth to deliver more business partnerships and clinical integrations with our simple, blood-based test solution for improved cancer screening as well as for our tumor monitoring research service.”
Guigley most recently served as the Chief Commercial Officer at Invitae, where he orchestrated a commercial reorganization to transition from a growth-centric to a sustainable profit model. He led his team to enhance revenue strategies, customer service efficiencies, and sales performance while achieving impressive NPS scores and growth targets. Before Invitae, Rob was the Chief Commercial Officer at Ambry Genetics, where he led significant commercial growth, including a COVID-19 testing program and an innovative program (Ambry CARE) that helped unlock the sizable untapped TAM in hereditary genetics.
Also Read: AbbVie Acquires Aliada Therapeutics to Boost Alzheimer’s Focus
“DELFI has the innovative approach, momentum, and leadership team to revolutionize cancer screening,” said Guigley. “I’ve dedicated my career to supporting leaders in healthcare that aim to challenge and disrupt the status quo, and I believe cancer screening markets are ready for DELFI’s approach. I’m thrilled to support the company as it propels market growth and increases patient access.”
Rob’s career also includes impactful roles at Omada Health and Counsyl, where he achieved notable revenue growth, developed strategic health plan initiatives, and built strong partnerships within the industry. He started his pharmaceutical career with AstraZeneca, where he consistently ranked among the top sales performers. He holds an MBA with honors from Boston University and a Bachelor’s degree in Economics from the University of Pittsburgh.
DELFI tests are built to solve the health issues of the highest-burden population, including those in historically underserved demographics. Its flagship test, FirstLook Lung, is for individuals eligible for lung cancer screening and requires a simple blood draw that can be incorporated with routine blood work. DELFI works with leading healthcare systems, including Allegheny Health Network, Indigenous PACT, OSF Healthcare, and City of Hope. In addition, Nature Communications just published a new paper demonstrating the effectiveness of DELFI Diagnostics’ cell-free DNA (cfDNA) fragmentomes in assessing tumor burden for treatment response, monitoring, and clinical outcome prediction.
SOURCE: PRNewswire